A Study of rhBMP-2/CPM in Closed Fractures of the Humerus

NCT00384852

Last updated date
Study Location
Little Rock, Arkansas, 72205, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Fractures
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Skeletally mature subjects age 18 years or older.

- Subjects with either a closed proximal humeral fracture or a diaphyseal humeral fracture.

- Treatment plan that includes only conservative (nonoperative) therapy within 48 hours following injury.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Shoulder dislocation at the time of injury.


- Planned procedure(s) at that would stimulate fracture union at the time of application
of the initial immobilization device.


- Fractures located in the distal third of humerus.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FracturesA Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures
NCT00387686
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Aurora, Colorado
  4. Denver, Colorado
  5. New Haven, Connecticut
  6. Pinellas Park, Florida
  7. Fort Wayne, Indiana
  8. Indianapolis, Indiana
  9. Baltimore, Maryland
  10. Kalamazoo, Michigan
  11. Portage, Michigan
  12. Lebanon, New Hampshire
  13. New Brunswick, New Jersey
  14. Brooklyn, New York
  15. Elmhurst, New York
  16. Charlotte, North Carolina
  17. Memphis, Tennessee
  18. Buenos Aires,
  19. Liverpool, New South Wales
  20. New Lambton, New South Wales
  21. Herston, Queensland
  22. Adelaide, South Australia
  23. Cerequeira Cesar, Sao Paolo
  24. Vila Clemetino, Sao Paulo
  25. Ajax, Ontario
  26. Oshawa, Ontario
  27. Scarborough, Ontario
  28. Windsor, Ontario
  29. Windsor, Ontario
  30. Montreal, Quebec
  31. Sherbrooke, Quebec
  32. Oulu,
  33. Turku,
  34. Angers,
  35. Créteil,
  36. Marseille,
  37. Toulouse,
  38. Berlin,
  39. Mainz,
  40. Muenster,
  41. Hyderabad, Andhra Pradesh
  42. Ahmedabad, Gujarat
  43. Mangalore, Karnataka
  44. Nagpur, Maharashtra
  45. Pune, Maharashtra
  46. Riga,
  47. Riga,
  48. Col. Los Morales, Del Miguel, Hidalgo
  49. Col. el Retiro, Guadalajara, Jal.
  50. Mexico City, Mexico D.F.
  51. Chihuahua,
  52. Guadalajara, Jal,
  53. Bielsk Podlaski,
  54. Krakow,
  55. Cluj-Napoca, Cluj
  56. Bucharest,
  57. Bucuresti,
  58. Bucuresti,
  59. Bucuresti,
  60. Iasi,
  61. Belgrade,
  62. Nis,
  63. Ljubljana,
  64. Alcala de Henares, Madrid
  65. Alcala,
  66. Madrid,
  67. Uppsala,
  68. Coventry,
  69. Norwich,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
FracturesFeasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures
NCT00384358
  1. Aurora, Colorado
  2. New Haven, Connecticut
  3. Clearwater, Florida
  4. Pinellas Park, Florida
  5. Decatur, Georgia
  6. New Brunswick, New Jersey
  7. Brooklyn, New York
  8. Elmhurst, New York
  9. Liverpool, New South Wales
  10. Herston, Queensland
  11. Adelaide, South Australia
  12. Melbourne, Victoria
  13. Parkville, Victoria
  14. Ajax, Ontario
  15. Chatham, Ontario
  16. Scarborough, Ontario
  17. Montreal, Quebec
  18. Oulu,
  19. Turku,
  20. Creteil,
  21. Marseille,
  22. Berlin,
  23. Muenster,
  24. Budapest,
  25. Debrecen,
  26. Bergen,
  27. Oslo,
  28. Link?ping,
  29. Edinburgh,
  30. Norwich,
ALL GENDERS
55 Years+
years
MULTIPLE SITES
FracturesA Study of rhBMP-2/CPM in Closed Fractures of the Humerus
NCT00384852
  1. Little Rock, Arkansas
  2. Aurora, Colorado
  3. Denver, Colorado
  4. Clearwater, Florida
  5. St. Petersburg, Florida
  6. Brooklyn, New York
  7. Monroe, North Carolina
  8. Toledo, Ohio
  9. State College, Pennsylvania
  10. Herston, Queensland
  11. Adelaide, South Australia
  12. Melbourne, Victoria
  13. Sao Paulo,
  14. Sao Paulo,
  15. São Paulo,
  16. Vancouver, British Columbia
  17. Ajax, Ontario
  18. Chatham, Ontario
  19. Oshawa, Ontario
  20. Scarborough, Ontario
  21. Windsor, Ontario
  22. Montreal, Quebec
  23. Charlottetown,
  24. Oulu,
  25. Turku,
  26. Angers,
  27. Creteil,
  28. Berlin,
  29. Muenster,
  30. Guadalajara, Jalisco
  31. Monterrey, Nuevo Leon
  32. Chihuahua,
  33. D.f.,
  34. Oslo,
  35. Bucharest,
  36. Bucharest,
  37. Bucharest,
  38. Linköping,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study of rhBMP-2/CPM in Closed Fractures of the Humerus
Official Title  ICMJE A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) as an Adjuvant Therapy in Closed Fractures of the Humerus
Brief Summary The primary objective of this study is to assess whether fracture union is accelerated in subjects with humeral fractures (proximal,diaphyseal) treated with conservative therapy (standard of care) and a single dose of rhBMP-2/CPM compared to subjects who receive standard of care alone.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Fractures
Intervention  ICMJE Drug: rhBMP-2/CPM
Study Arms  ICMJE
  • Experimental: A
    1.0 mg/mL rhBMP-2/CPM + SOC
    Intervention: Drug: rhBMP-2/CPM
  • Experimental: B
    2.0 mg/mL rhBMP-2/CPM + SOC
    Intervention: Drug: rhBMP-2/CPM
  • Active Comparator: C
    Buffer/CPM + SOC
    Intervention: Drug: rhBMP-2/CPM
  • D
    Standard of Care Alone (SOC)
    Intervention: Drug: rhBMP-2/CPM
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 12, 2010)
139
Original Enrollment  ICMJE
 (submitted: October 3, 2006)
132
Actual Study Completion Date  ICMJE February 2010
Actual Primary Completion Date February 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Skeletally mature subjects age 18 years or older.
  • Subjects with either a closed proximal humeral fracture or a diaphyseal humeral fracture.
  • Treatment plan that includes only conservative (nonoperative) therapy within 48 hours following injury.

Exclusion Criteria:

  • Shoulder dislocation at the time of injury.
  • Planned procedure(s) at that would stimulate fracture union at the time of application of the initial immobilization device.
  • Fractures located in the distal third of humerus.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Brazil,   Canada,   Finland,   France,   Germany,   Mexico,   Norway,   Romania,   Sweden,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00384852
Other Study ID Numbers  ICMJE 3100N7-212
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Wyeth is now a wholly owned subsidiary of Pfizer
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator:Trial ManagerFor Brazil, [email protected]
Principal Investigator:Trial ManagerFor Mexico, [email protected]
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP